The taxanes: Dosing and scheduling considerations

ONCOLOGY

Volumn 11, Issue 3 SUPPL. 2, 1997, Pages 7-19

  Rowinsky, Eric K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; OVARY CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0030960062     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (88)

1. Arbuck SG, Canetta R, Onetto N, et al: Current dosage and scheduling issues in the development of paclitaxel (TAXOL) Semin Oncol 4(suppl 3):31-39, 1993.
2. Arbuck SA, Blaylock B: Dose and Schedule Issues, in McGuire WP, Rowinsky EK (eds): Paclitaxel in Cancer Treatment, pp 151-173. Marcel Dekker, New York, 1995.
3. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565, 1970.
4. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into raicrotubules induced by Taxol and Taxotere. Biochemistry 32:2747-2755, 1993.
5. Bissery M-C, Nohynek, Sanderlink G-J, et al: Docetaxel (Taxotere): a review of preclinical and clinical experience: Part I: preclinical experience. Anti-Cancer Drugs 6:339-355, 1995.
6. Ringel I, Horwitz SB: Studies with RP56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991.
7. Jordon MA, Wendell K, Gardiner S, et al: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825, 1996.
8. Haldar S, Chintapalli J, Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253-1255, 1996.
9. Schiff PB, Gubits R, Kashimawo, et al: Paclitaxel with ionizing radiation, in WG McGuire, Rowinsky EK (eds): Paclitaxel in Cancer Treatment, pp 81-90. Marcel Dekker, New York, 1995.
10. Belotti D, Rieppi M, Nicoletti MI, et al: Paclitaxel inhibits motility of paclitaxel resistant human ovarian cancer cell. Clin Cancer Res 2:1725-1730, 1996.
11. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849, 1996.
12. Rowinsky EK, Donehower RC, Jones RJ, et al: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48:4093-4100, 1988.
13. Horwitz SB, Cohen D, Rao S, et al: Taxol: Mechanisms of action and resistance. Monogr Natl Cancer Inst 15:63-67, 1993.
14. Bhalla K, Ibrado AM, Tourkina E, et al: Taxol induces intranucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7:563-568, 1993.
15. Jordan MA, Toso RJ, Thrower D, et al: Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci 90:9552-9556, 1993.
16. Jordan MA, Thrower D, Wilson L: Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51:2212, 1991.
17. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993.
18. Helson L, Helson C, Malik S, et al: A saturation threshold for Taxol cytotoxicity in human glial and neuroblastoma cells. Anti-Cancer Drugs 4:487-490, 1993.
19. Riccardi R, Servidei T, Spiridigliozzi A, et al: Cytotoxicity of Taxol in neuroblastoma SH-SY5Y and medulloblastoma TE-671 cell lines in vitro. 8th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 195, March 15-18, 1994.
20. Liebmann JE, Cook JA, Lipschultz C, et al: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68:1104-1109, 1993.
21. Rhiou JF, Naudin A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164-170, 1992.
22. Hill BT, Whelan RHD, Shellard SA, et al: Differential cytotoxic effects of docetaxel in a range of mammalian tumour cell lines and certain drug resistant cell lines in vitro. Invest New Drugs 12:169-182, 1994.
23. Rowinsky EK, Donehower RC, Tucker RW: Microtubule changes and cytotoxicity produced by Taxol in human ovarian cell lines. Proc Am Assoc Cancer Res 28:423, 1987.
24. Georgiadis MS, Russell E, Johnson BE: Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Proc Int Assoc Study Lung Cancer 11:95, 1994.
25. Figg WD, Thibault A, McCall NA, et al: The in vitro activity of Taxol on three hormone refractory prostate cancer cell lines, PC3. DU145, and PC3M. Proc Am Assoc Cancer Res 35:431, 1994.
26. Zhan Z, Kang Y-K, Regis J, et al: Taxol resistance: In vitro and in vitro studies in breast cancer and lymphoma. Proc Am Assoc Cancer Res 34:215, 1993.
27. Lai GM, Chen YN, Mickley LA, et al: P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49:696-703, 1991.
28. Cahan MA, Walter KA, Colvin OM, et al: Cytotoxicity of Taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33:441-444, 1994.
29. Kelland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450, 1992.
30. Wilson L, Miller HP, Farrell KW, et al: Taxol stabilization of microtubules in vitro. Biochemistry 24:5254-5262, 1985.
31. Parness J, Horwitz SB: Taxol binds to polymerized microtubules in vitro. J Cell Biol 91:479-487, 1981.
32. Collins CA, Vallee RB: Temperature-dependent reversible assembly of Taxol-treated microtubules. J Cell Biol 105:2847-2854, 1987.
33. Lavelle F, Fizames C, Gueritte-Voegelein F, et al: Experimental properties of RP 56976, a Taxol derivative. Proc Am Assoc Cancer Res 30:2254, 1989.
34. Kelland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol 30:444-450, 1992.
35. Braakhuis BMJ, Hill BT, Dietel M, et al: In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol), and cisplatin against human tumours and normal bone marrow cells. Anticancer Res 14:205-208, 1994.
36. Garcia P, Braguer D, Carles G, et al: Comparative effects of Taxol and Taxotere on different human carcinoma cell lines. Cancer Chemother. Pharmacol 34:335-343, 1994.
37. Young DH, Michelotti EL, Swindell CS, et al: Antifungal properties of Taxol and various analogues. Experientia 4:882-885, 1992.
38. National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, NCI, Bethesda, MD, 1993.
39. Rose WC: Taxol: A review of its preclinical in vitro antitumor activity. Anticancer Drugs 3:311-321, 1992.
40. Rose, WC: Taxol-based combination chemotherapy and other in vitro preclinical antitumor studies Monogr Natl Cancer Inst 15:47-53, 1993.
41. Stearns ME, Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3ML) invasion and metastases. Cancer Res 52:3776-3681, 1992.
42. Medalia O, Aronson M, Ringel I, et al: Inhibition of mouse bladder tumor growth by intravesicular installation of Taxol. Proc Am Assoc Cancer Res 35:325, 1994.
43. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational anticancer agent. J Natl Cancer Inst 82:1247-1259, 1990.
44. Apfel SC, Lipton RB, Arezzo JC, et al: Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29:87-90, 1991.
45. Roytta M, Horwitz SB, Raine CS: Taxol-induced neuropathy: Short-term effects of local injection. J Neurocytol 13:685-671, 1984.
46. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumour activity of Taxotere (RP 57976, NSC 628503), a Taxol analog Cancer Res 51:4845-4852, 1991.
47. Bruno R, Sanderink GJ: Pharmacokinetics of Taxotere. Cancer Surveys 17:305-313, 1993.
48. Rowinsky EK, Donehower RC: Antimicrotubule Agents, in Chabner BA, Longo DL (eds): Cancer Chemotherapy, pp 263-296. Lippincott-Raven, Philadelphia, 1996.
49. Rowinsky EK, Wright M, Monsarrat B, et al: Taxol: Pharmacology, metabolism, and clinical implications. Cancer Surveys 17:283-304, 1993.
50. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22(suppl 6): 16-23, 1995.
51. van Oosterom AT, Schrijvers D: Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs 6:356-358, 1995.
52. 3H]paclitaxel in rats. Cancer Chemother Pharmacol, 1997 (in press).
53. Eiseman JL, Eddington ND, Leslie J, et al: Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465-471, 1994.
54. 14C-RP 56976) in mice and dogs. Proc Am Assoc Cancer Res 34:393, 1993.
55. 14C-radiolabelled Taxotere (RP56976, NSC628503) in cancer patients. Proc Am Assoc Cancer Res 34:373, 1993.
56. Monsarrat B, Alvinerie P, Wright M, et al: Hepatic metabolism and biliary excretion of Taxol in rats and humans. Monogr J Natl Can Inst 15:39-46, 1993.
57. Walle T, Walle UK, Kumar GN, et al: Taxol metabolism and disposition in cancer patients. Drug Met Disp 23:506-512, 1995.
58. Gaver RC, Deeb G, Willey T, et al: The disposition of paclitaxel (Taxol) in the rat. Proc Am Assoc Cancer Res 34:390, 1993.
59. Eisenhauer E, ten Bokkel Huinink W, Swenerton KD, et al: European-Canadian randomized trial of Taxol in relapsed ovarian cancer: High vs low dose and long vs short infusion. J Clin Oncol 12:2654-2666, 1994.
60. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96 hour infusion. J Clin Oncol 12:1621-1629, 1994.
61. Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996.
62. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 13:1609-14, 1995.
63. Rowinsky EK, Onetto N, Canetta RM, et at: Taxol: the prototypic taxane, an important new class of antitumor agents. Semin Oncol 19:646-662, 1992.
64. Rowinsky EK, Donehower RC: Drug therapy: Paclitaxel (Taxol). N Engl J Med 332:1004-1114, 1995.
65. Cortex JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995.
66. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-70, 1992.
67. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Clin Inst 86:18-24, 1994.
68. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989.
69. Thigpen T, Blessing J, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecological Oncology Group study. J Clin Oncol 12:1748-1753, 1994.
70. Einzig AI, Wiernik P, Sasloff J, et al: Phase II study and long-term follow up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992.
71. Reed E, Bitton R, Sarosy G, et al: Paclitaxel dose intensity. J Infus Chemother 6:59-63, 1996.
72. Rowinsky EK, Mackey MK, Goodman SN: Meta analysis of paclitaxel dose-response and dose-intensity in recurrent or refractory ovarian cancer. Proc Am Soc Clin Oncol 15:284, 1996.
73. Omura GA, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel at 2 dose levels and Filgastrim (G; G-CSF) at 2 dose levels in platinum pretreated epithelial ovarian cancer (OVCA): A Gynecologic Oncology Group, SWOG, NCTTG and ECOG study. Proc Am Soc Clin Oncol 15:280, 1996.
74. Nabholtz J-M, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996.
75. Ravdin P, Burns HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
76. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995.
77. Rhone-Poulenc Rorer: Data on file.
78. Hudis CA, Seidman AD, Crown JPA, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer J Clin Oncol 14:58-65, 1996.
79. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995.
80. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer. A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 4:422-428, 1996.
81. 2 as first-line chemotherapy for patients with advanced breast cancer. Report of the Clinical Screening Group of the EORTC. Br J Cancer 74:650-656, 1996.
82. Peretz T, Sulkes A, Chollet P, et al: A multicenter randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31A (suppl 5):S75, 1995.
83. Bristol-Myers Squibb: Data on file.
84. Velero V, Burns HA, Jones SE, et al: Multicenter pilot study of Taxotere in Taxol-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 15:95, 1996.
85. Kunitoh H, Watanabe K, Onoshi T, et al: Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer. J Clin Oncol 14:1649-1655, 1996.
86. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin-granulocyte-colony-stimulating factor versus Taxol-cisplatin in advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 15:382, 1996.
87. Rowinsky EK, Bonomi P, Jiroutek M, et al: Pharmacodynamic studies of paclitaxel in ECOG 5592: A phase III trial comparing etoposide plus cisplatin vs low-dose paclitaxel plus cispiatin vs high-dose paclitaxel plus cisplatin plus G-CSF in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol, 1997 (in press).
88. Forastiere AA, Leong T, Murphy B, et al: A phase III trial of high dose paclitaxel + cisplatin + G-CSF versus low dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol, 1997 (in press).